Who
Scott D. Sandell
Director
Company insider
Files Form 4 as: Director and 10% owner, Cloudflare; Director and 10% owner, Coursera; 10% owner, Korro Bio; 10% owner, SpyGlass Pharma; Director and 10% owner, NeueHealth; 10% owner, Trevi Therapeutics; 10% owner, MBX Biosciences; 10% owner, Sagimet Biosciences.
In numbers
- Trades disclosed
- 1,310
- Buys
- 99
- Sells
- 128
- Bought
- $671.2M
- Sold
- $1.1B
- Companies
- 82
- Companies where not an officer
- 82
- First trade
- 1 Feb 2006
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | NET CloudflareCybersecurity | SEC FORM 4 Code A | —842 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | NET CloudflareCybersecurity | SEC FORM 4 Code A | —842 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | COUR CourseraSoftware | SEC FORM 4 Code A | —34,260 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | COUR CourseraSoftware | SEC FORM 4 Code A | —34,260 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Bought | $2.3M207,100 at $11.11 | filing |
| 10 Mar 2026filed 12 Mar 2026 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code P | $2.7M242,945 at $11.11 | filing |
| 10 Mar 2026filed 12 Mar 2026 | KRRO Korro Biooption or derivative · Biotechnology | SEC FORM 4 Code P | $2.7M242,945 at $11.11 | filing |
| 10 Mar 2026filed 12 Mar 2026 | KRRO Korro BioBiotechnology | SEC FORM 4 Bought | $2.3M207,100 at $11.11 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass PharmaMedical Devices | SEC FORM 4 Code C | —1,619,240 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass Pharmaoption or derivative · Medical Devices | SEC FORM 4 Code C | —1,370,168 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass Pharmaoption or derivative · Medical Devices | SEC FORM 4 Code C | —737,962 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass Pharmaoption or derivative · Medical Devices | SEC FORM 4 Code C | —954,990 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass Pharmaoption or derivative · Medical Devices | SEC FORM 4 Code C | —402,273 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass PharmaMedical Devices | SEC FORM 4 Code C | —1,370,168 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass PharmaMedical Devices | SEC FORM 4 Code C | —1,370,168 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass Pharmaoption or derivative · Medical Devices | SEC FORM 4 Code C | —1,619,240 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass Pharmaoption or derivative · Medical Devices | SEC FORM 4 Code C | —1,370,168 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass Pharmaoption or derivative · Medical Devices | SEC FORM 4 Code C | —1,370,168 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass Pharmaoption or derivative · Medical Devices | SEC FORM 4 Code C | —737,962 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SGP SpyGlass Pharmaoption or derivative · Medical Devices | SEC FORM 4 Code C | —954,990 | filing |
The newest 500 lines are listed; the numbers count every line.
News
SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL SystemSGP · manilatimes.net · 19 Oct 2026BioLineRx (NASDAQ:BLRX) and Korro Bio (NASDAQ:KRRO) Head to Head SurveyKRRO · dailypolitical.com · 14 Oct 2026Contrasting BioLineRx (NASDAQ:BLRX) & Korro Bio (NASDAQ:KRRO)KRRO · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Scott D. Sandell; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.